vs
因美纳（ILMN）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
瑞思迈的季度营收约是因美纳的1.2倍（$1.4B vs $1.2B），因美纳净利率更高（28.8% vs 27.6%，领先1.2%），瑞思迈同比增速更快（11.0% vs 5.0%），瑞思迈自由现金流更多（$311.2M vs $267.0M），过去两年瑞思迈的营收复合增速更高（9.0% vs -0.7%）
因美纳是总部位于美国加利福尼亚州圣迭戈的生物技术企业，成立于1998年4月，专注研发、生产及销售用于分析基因变异与生物功能的集成系统，产品及服务覆盖测序、基因分型、基因表达、蛋白质组学等领域，业务遍及全球超155个国家和地区。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
ILMN vs RMD — 直观对比
营收规模更大
RMD
是对方的1.2倍
$1.2B
营收增速更快
RMD
高出6.0%
5.0%
净利率更高
ILMN
高出1.2%
27.6%
自由现金流更多
RMD
多$44.2M
$267.0M
两年增速更快
RMD
近两年复合增速
-0.7%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.2B | $1.4B |
| 净利润 | $334.0M | $392.6M |
| 毛利率 | 65.5% | 61.8% |
| 营业利润率 | 17.4% | 34.6% |
| 净利率 | 28.8% | 27.6% |
| 营收同比 | 5.0% | 11.0% |
| 净利润同比 | 185.5% | 13.9% |
| 每股收益（稀释后） | $2.16 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ILMNRMD
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | $1.1B | $1.3B | ||
| Q3 24 | $1.1B | $1.2B | ||
| Q2 24 | $1.1B | $1.2B | ||
| Q1 24 | $1.1B | $1.2B |
净利润ILMNRMD
| Q4 25 | $334.0M | $392.6M | ||
| Q3 25 | — | $348.5M | ||
| Q2 25 | — | $379.7M | ||
| Q1 25 | — | $365.0M | ||
| Q4 24 | $186.0M | $344.6M | ||
| Q3 24 | $705.0M | $311.4M | ||
| Q2 24 | $-2.0B | $292.2M | ||
| Q1 24 | $-126.0M | $300.5M |
毛利率ILMNRMD
| Q4 25 | 65.5% | 61.8% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 60.8% | ||
| Q1 25 | — | 59.3% | ||
| Q4 24 | 65.9% | 58.6% | ||
| Q3 24 | 69.0% | 58.6% | ||
| Q2 24 | 64.8% | 58.5% | ||
| Q1 24 | 62.0% | 57.9% |
营业利润率ILMNRMD
| Q4 25 | 17.4% | 34.6% | ||
| Q3 25 | — | 33.4% | ||
| Q2 25 | — | 33.7% | ||
| Q1 25 | — | 33.0% | ||
| Q4 24 | 15.8% | 32.5% | ||
| Q3 24 | 68.6% | 31.6% | ||
| Q2 24 | -147.2% | 31.2% | ||
| Q1 24 | -10.3% | 31.3% |
净利率ILMNRMD
| Q4 25 | 28.8% | 27.6% | ||
| Q3 25 | — | 26.1% | ||
| Q2 25 | — | 28.2% | ||
| Q1 25 | — | 28.3% | ||
| Q4 24 | 16.8% | 26.9% | ||
| Q3 24 | 65.3% | 25.4% | ||
| Q2 24 | -178.8% | 23.9% | ||
| Q1 24 | -11.7% | 25.1% |
每股收益（稀释后）ILMNRMD
| Q4 25 | $2.16 | $2.68 | ||
| Q3 25 | — | $2.37 | ||
| Q2 25 | — | $2.58 | ||
| Q1 25 | — | $2.48 | ||
| Q4 24 | $1.16 | $2.34 | ||
| Q3 24 | $4.42 | $2.11 | ||
| Q2 24 | $-12.48 | $1.97 | ||
| Q1 24 | $-0.79 | $2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6B | $1.4B |
| 总债务越低越好 | — | $403.9M |
| 股东权益账面价值 | $2.7B | $6.3B |
| 总资产 | $6.6B | $8.5B |
| 负债/权益比越低杠杆越低 | — | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资ILMNRMD
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $932.7M | ||
| Q4 24 | $93.0M | $521.9M | ||
| Q3 24 | $70.0M | $426.4M | ||
| Q2 24 | $74.0M | $238.4M | ||
| Q1 24 | — | $237.9M |
总债务ILMNRMD
| Q4 25 | — | $403.9M | ||
| Q3 25 | — | $408.7M | ||
| Q2 25 | — | $658.4M | ||
| Q1 25 | — | $663.1M | ||
| Q4 24 | — | $662.9M | ||
| Q3 24 | — | $667.6M | ||
| Q2 24 | — | $697.3M | ||
| Q1 24 | — | $997.0M |
股东权益ILMNRMD
| Q4 25 | $2.7B | $6.3B | ||
| Q3 25 | — | $6.1B | ||
| Q2 25 | — | $6.0B | ||
| Q1 25 | — | $5.5B | ||
| Q4 24 | $2.4B | $5.3B | ||
| Q3 24 | $2.1B | $5.2B | ||
| Q2 24 | $1.4B | $4.9B | ||
| Q1 24 | $5.7B | $4.6B |
总资产ILMNRMD
| Q4 25 | $6.6B | $8.5B | ||
| Q3 25 | — | $8.3B | ||
| Q2 25 | — | $8.2B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $6.3B | $7.1B | ||
| Q3 24 | $6.0B | $7.2B | ||
| Q2 24 | $6.1B | $6.9B | ||
| Q1 24 | $10.0B | $6.8B |
负债/权益比ILMNRMD
| Q4 25 | — | 0.06× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.11× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 0.13× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $321.0M | $339.7M |
| 自由现金流经营现金流 - 资本支出 | $267.0M | $311.2M |
| 自由现金流率自由现金流/营收 | 23.0% | 21.9% |
| 资本支出强度资本支出/营收 | — | 2.0% |
| 现金转化率经营现金流/净利润 | 0.96× | 0.87× |
| 过去12个月自由现金流最近4个季度 | $935.0M | $1.8B |
8季度趋势，按日历期对齐
经营现金流ILMNRMD
| Q4 25 | $321.0M | $339.7M | ||
| Q3 25 | — | $457.3M | ||
| Q2 25 | — | $538.8M | ||
| Q1 25 | — | $578.7M | ||
| Q4 24 | $364.0M | $308.6M | ||
| Q3 24 | $316.0M | $325.5M | ||
| Q2 24 | $80.0M | $440.1M | ||
| Q1 24 | $77.0M | $402.0M |
自由现金流ILMNRMD
| Q4 25 | $267.0M | $311.2M | ||
| Q3 25 | — | $414.4M | ||
| Q2 25 | — | $508.2M | ||
| Q1 25 | — | $557.9M | ||
| Q4 24 | $335.0M | $288.0M | ||
| Q3 24 | $284.0M | $307.7M | ||
| Q2 24 | $49.0M | $415.2M | ||
| Q1 24 | $41.0M | $380.8M |
自由现金流率ILMNRMD
| Q4 25 | 23.0% | 21.9% | ||
| Q3 25 | — | 31.0% | ||
| Q2 25 | — | 37.7% | ||
| Q1 25 | — | 43.2% | ||
| Q4 24 | 30.3% | 22.5% | ||
| Q3 24 | 26.3% | 25.1% | ||
| Q2 24 | 4.4% | 33.9% | ||
| Q1 24 | 3.8% | 31.8% |
资本支出强度ILMNRMD
| Q4 25 | — | 2.0% | ||
| Q3 25 | — | 3.2% | ||
| Q2 25 | — | 2.3% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | 2.6% | 1.6% | ||
| Q3 24 | 3.0% | 1.5% | ||
| Q2 24 | 2.8% | 2.0% | ||
| Q1 24 | 3.3% | 1.8% |
现金转化率ILMNRMD
| Q4 25 | 0.96× | 0.87× | ||
| Q3 25 | — | 1.31× | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | 1.59× | ||
| Q4 24 | 1.96× | 0.90× | ||
| Q3 24 | 0.45× | 1.05× | ||
| Q2 24 | — | 1.51× | ||
| Q1 24 | — | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ILMN
| Product revenue | $990.0M | 85% |
| Service and other revenue | $169.0M | 15% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
